Cyclerion Therapeutics (CYCN) 10-Q2021 Q1 Quarterly report

Filed: 30 Apr 21, 4:04pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: aging, allosteric, brain, break, consecutive, CSF, differentiated, DN, footnote, forfeited, intercompany, mission, network, node, omitted, opinion, Partnership, quoted, recipient, restore, reverse, reversed, RSU, schizophrenia, Startup

Removed: accredited, added, allocation, American, amortized, approach, arising, arrangement, attributable, audit, August, back, borrow, buildout, calculate, calculated, capitalized, carve, central, centralized, clarification, cloud, codification, combined, computing, conform, conformity, construction, created, creation, customer, deemed, Deficit, Delaware, depended, depreciated, deterioration, determining, directly, disbursed, discount, discounted, divested, donated, donor, Dr, Endowment, enhance, enrolled, entering, environment, equal, evidence, expanding, expedient, fairly, financed, framework, funded, guidance, Hecht, Hedging, higher, hosting, IBR, identifiable, identification, implementation, implicit, improvement, inception, inconsistent, incur, individually, infrastructure, initially, intend, interpretation, invested, irrevocably, issuance, joined, judge, large, leasing, license, lieu, line, litigation, local, location, managed, measurement, mild, mutual, obligated, order, organizational, outsourced, outsourcing, owner, parent, partial, participated, patient, pattern, pending, peripheral, Peter, pharmacological, philosophy, placebo, plant, population, portion, practicable, practical, preliminary, presently, pressure, principally, procurement, project, put, qualifying, qualitative, quality, quantitative, randomized, recording, reducing, refer, reflection, relationship, relief, Requirement, restructuring, SCD, shared, shorter, similarly, single, site, software, specific, staggering, supporting, targeted, temporary, tenant, terminating, threatened, top, trade, transfer, treasury, troubled, uncertainty, usage, vacating, work

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CYCN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Peter M. Hecht, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report on Form 10-Q of Cyclerion Therapeutics, Inc. for the period ended March 31, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Cyclerion Therapeutics, Inc.

Date: April 30, 2021	By:	/s/ Peter M. Hecht
	Name:	Peter M. Hecht
	Title:	Chief Executive Officer (Principal Executive Officer)